Association of intratumoral CD68+CD163+ M2-like macrophages with survival in metastatic colorectal cancer treated with chemotherapy plus bevacizumab
Open Access
- 17 July 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1845691
Abstract
Background: Metastatic colorectal cancer (mCRC) is a common and highly lethal gastrointestinal malignancy. Although chemotherapy combined with bevacizumab is a standard first-line treatment, post-treatment resistance severely limits patients’ long-term survival. While the remodeling of tumor-associated macrophages (TAMs) is closely related to targeted therapy resistance, the specific impact of TAMs and their programmed death-ligand 1 (PD-L1) expression on post-treatment resistance and prognosis remains unclear. This study aimed to investigate the spatial distribution and immunophenotypic characteristics of CD68 + CD163 + M2-like TAMs and their association with post-treatment resistance and survival. Methods: We retrospectively analyzed clinical data and tumor tissues from 44 patients with mCRC who received first-line chemotherapy plus bevacizumab and were categorized into resistant and non-resistant groups. Multiplex immunofluorescence and digital image-based quantitative analysis were used to evaluate macrophage markers (CD68 and CD163) and PD-L1 expression in the whole tumor section, tumor areas, and stromal areas. Results: Compared with the non-resistant group, resistant patients showed significantly increased proportions and densities of CD68 + CD163 + M2-like TAMs and CD68 + CD163 + PD-L1 + M2-like TAMs in the tumor areas (all p < 0.05). The infiltration levels of these macrophage subsets were significantly associated with post-treatment resistance, but not with conventional clinicopathological features such as sex, age, or tumor stage. Survival analysis showed that a high density of intratumoral CD68 + CD163 + M2-like TAMs was significantly associated with shorter overall survival (OS) (p < 0.05) and showed a trend toward shorter progression-free survival (PFS) (p = 0.06). Multivariate Cox regression further demonstrated that dense intratumoral infiltration of CD68 + CD163 + M2-like TAMs was independently associated with unfavorable OS and PFS. Conclusion: In mCRC patients exhibiting resistance to chemotherapy combined with bevacizumab, the infiltration of intratumoral CD68 + CD163 + M2-like TAMs and their PD-L1-expressing subsets is significantly elevated. Notably, a high density of intratumoral CD68 + CD163 + M2-like TAMs serves as an independent poor prognostic marker for both PFS and OS. These findings demonstrate that the spatial enrichment of CD68 + CD163 + M2-like TAMs within the tumor microenvironment is closely associated with treatment resistance, suggesting that macrophage-targeted interventions may represent a potential strategy to enhance the efficacy of anti-tumor therapies in mCRC.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (ZR2022QH055)
This publication has 47 references indexed in Scilit:
- The implied dysregulated RKIP-hypoxia axis in cancer and immune evasion: Clinical implicationsDrug Resistance Updates, 2025
- Prognostic value of CD163+ macrophages in solid tumor malignancies: A scoping reviewImmunology Letters, 2025
- Cancer incidence and mortality in China, 2022Journal of the National Cancer Center, 2024
- The role of cluster of differentiation 163-positive macrophages in wound healing: a preliminary study and a systematic reviewArchives of Dermatological Research, 2022
- PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expressionInternational Immunopharmacology, 2021
- Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapyCancer Communications, 2020
- Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal CancerClinical Colorectal Cancer, 2019
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directionsAngiogenesis, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- T Cell Recognition of Human Tumors: Implications for Molecular Immunotherapy of CancerClinical Immunology and Immunopathology, 1993